Welcome to our dedicated page for Deciphera Pharmaceuticals news (Ticker: DCPH), a resource for investors and traders seeking the latest updates and insights on Deciphera Pharmaceuticals stock.
Deciphera Pharmaceuticals, Inc. (symbol: DCPH) is a biotechnology company founded in 2003 with a deep scientific understanding of kinase inhibitors. Based in Boston, with research capabilities near the University of Kansas, Deciphera specializes in developing advanced kinase-inhibiting drugs for cancer and immunological diseases. The company has identified small molecule leads for over 50 kinase targets and has built a robust pipeline of drug candidates, including three clinical-stage and two research-stage programs.
The company's lead drug candidate, DCC-2618, is designed to inhibit mutant or amplified KIT and Pdgfra kinases, which drive cancers such as gastrointestinal stromal tumors, advanced systemic mastocytosis, gliomas, and other solid tumors. In addition, Deciphera is developing two other clinical-stage drug candidates, DCC-3014 and Rebastinib, which are focused on treating different types of cancers.
Geographically, Deciphera's operations are concentrated in the United States. The company has recently achieved significant milestones, including the successful completion of a tender offer by Ono Pharmaceutical Co., Ltd. to acquire all outstanding shares of Deciphera for approximately $2.4 billion. Following this acquisition, Deciphera became a wholly owned subsidiary of Ono, who will leverage its research and development capabilities in oncology and its sales power in Europe and the United States to expand its global presence.
The merger with Ono Pharmaceutical marks a new phase for Deciphera, where the combined expertise and resources are expected to accelerate the growth of their pipeline and contribute significantly to the global fight against cancer and other diseases.
Ono Pharmaceutical has completed the acquisition of Deciphera Pharmaceuticals after a successful tender offer of $25.60 per share, totaling approximately $2.4 billion. The tender offer began on May 13, 2024, and concluded on June 10, 2024, with 88.25% of Deciphera's shares tendered. Upon completion, Deciphera merged into Ono's subsidiary, becoming a wholly-owned entity and delisted from Nasdaq. Ono aims to leverage Deciphera's R&D capabilities and sales networks in oncology to enhance its global expansion. The acquisition is expected to accelerate Ono's pipeline growth and strengthen its position in the global market.
Deciphera Pharmaceuticals announced the Phase 3 results of their MOTION study on vimseltinib for treating tenosynovial giant cell tumor (TGCT) at the 2024 ASCO Annual Meeting and in The Lancet. The study showed significant efficacy, quality-of-life improvements, and a well-tolerated safety profile. The company plans to submit a New Drug Application (NDA) in Q2 2024 and a Marketing Authorization Application (MAA) in Q3 2024. Key findings included a 40% overall response rate (ORR) for vimseltinib compared to 0% for placebo, significant improvements in range of motion, physical function, and pain reduction. Vimseltinib was well tolerated with mainly mild side effects. Additionally, Deciphera is conducting a Phase 1/2 study of DCC-3116 in combination with ripretinib for advanced gastrointestinal stromal tumors, currently in the dose escalation phase.
ONO Pharmaceutical, Co., , is set to acquire Deciphera Pharmaceuticals, Inc. for approximately US $2.4 billion. The deal involves a cash offer of US $25.60 per share, representing a premium of 74.7% to Deciphera's closing share price. The acquisition aims to strengthen ONO's oncology pipeline, expand global reach, and leverage Deciphera's commercial and research capabilities.
Deciphera Pharmaceuticals, Inc., a biopharmaceutical company focused on cancer treatment, is set to be acquired by ONO Pharmaceutical Co., for $2.4 billion. Shareholders will receive $25.60 per share in cash. The merger will combine Deciphera's kinase inhibitor expertise and commercialization platform with ONO's pipeline to accelerate global drug delivery.
FAQ
What is the current stock price of Deciphera Pharmaceuticals (DCPH)?
What is the market cap of Deciphera Pharmaceuticals (DCPH)?
What does Deciphera Pharmaceuticals, Inc. specialize in?
Where is Deciphera Pharmaceuticals based?
What are the key drug candidates in Deciphera's pipeline?
What is DCC-2618 designed to treat?
Who acquired Deciphera Pharmaceuticals and for how much?
What will be the impact of the acquisition by Ono Pharmaceutical on Deciphera Pharmaceuticals?
What is the significance of Deciphera becoming a wholly owned subsidiary of Ono?
What are the research capabilities of Deciphera Pharmaceuticals?
Are Deciphera's operations limited to the United States?
What recent achievements has Deciphera Pharmaceuticals accomplished?
